Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .
Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
BACKGROUND We assessed and directly compared weight loss effects of sibutramine and orlistat treatment in a group of obese , poorly-controlled type 2 diabetic patients . METHODS This study recruited 34 diabetic subjects [ glycohemoglobin ( HbA1c ) > 8 % ] with a body mass index of at least 27 kg/m2 . A 36-week , three-phase , prospect i ve , r and omized , cross-over comparative study was conducted . In phase 1 , 34 patients were r and omly divided into two groups . One group received sibutramine for 3 months , then completed a 3 month wash-out period and , finally , shifted to orlistat for another 3 months . The second group followed the same procedure but received orlistat first and then sibutramine . The efficacy measures were rate of weight reduction , glycemic control , insulin sensitivity and cardiovascular risk factors , including waist circumference , lipid profiles and blood pressure . RESULTS The sibutramine-treated group achieved 2.0 kg ( 2.5 % ) weight loss with observable but not statistically significant changes in insulin sensitivity , glycemic control , and cardiovascular risk factors . There were no significant changes in systolic or diastolic blood pressure . The weight reduction in the orlistat-treated group was only 0.8 kg ( 0.9 % ) , which was significantly less than that of the sibutramine group . There were significant differences in total cholesterol , low density lipoprotein cholesterol and HbA1C . Direct comparative analysis revealed no significant differences between these two groups . CONCLUSION This study indicates that sibutramine treatment produced greater reduction in weight than orlistat in obese , poorly-controlled type 2 diabetic patients . However , no significant differences in waist circumference , and lipid or glucose levels were found between the two groups
Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .